| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC70332 | CU-CPD107 Featured | CU-CPD107 is a TLR8-specific small molecule with unique synergistic agonist activities in the presence of ssRNA, but inactive without the aid of ssRNA.CU-CPD107 significantly inhibited of R848-induced signaling in HEK-Blue hTLR8 cells with an IC50 of 13.7 uM.CU-CPD107 only inhibited synthesized small-molecule agonist-induced TLR8 signaling without affecting other TLRs.CU-CPD107 synergistically increased IFN-β, TNF-α, IL-1β, IL-6, and IL-8 mRNA expression levels in the presence of 5 μg/ml ssRNA40 in HEK-Blue hTLR8 cells, whereas CU-CPD107 alone did not. CU-CPD107 only activated TLR8-mediated signaling in the presence of ssRNA.CU-CPD107 showed no pure agonistic activity, addressing a major challenge that has existed for previous TLR7 and TLR8 agonists as vaccine adjuvants or antiviral drugs. |
|
| DC60236 | Imiquimod hydrochloride Featured | Imiquimod hydrochloride (R 837 hydrochloride), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod hydrochloride exhibits antiviral and antitumor effects in vivo. Imiquimod hydrochloride can be used for the research of external genital, perianal warts, cancer and COVID-19. |
|
| DCC3219 | Malp-2 Featured | Toll-like receptor 2/6 (TLR-2/6) agonist, regulating Lcn2 gene, promoting collateral growth |
|
| DCC4810 | Smu-z1 Featured | Novel potent TLR1/2 Specific Agonist, Suppressing Leukemia Cancer Cell Growth by Stimulating Cytotoxic T Lymphocytes |
|
| DCC4995 | Szu101 Featured | Novel TLR7 agonist via immune response induction and tumor microenvironment modulation |
|
| DCC5384 | Vb-201 Featured | Novel anticryptosporidial agent, acting as a toll-like receptor-2 (TLR2) antagonist |
|
| DC73561 | E104 Featured | E014 is a potent, selective TLR7 agonist with EC50 of 69 nM in Ramos Blue reporter assays, >500-fold selective for TLR7 over TLR8. |
|
| DC73563 | E6742 Featured | E6742 (E6742) is a potent, selective, dual TLR7/8 inhibitor with binding Kd of 1.7 uM/37 nM in ITC assays, respectively, inhibits TLR7/8 agonist CL097 induced reporter activation with IC50 values of 22, 68, and 3.0 nM for hTLR7, mTLR7, and hTLR8, respecti |
|
| DC66322 | WAY-327512 Featured | activate TLR8-dependent NF-kB signaling |
|
| DC66456 | TLR7/8 agonist 1 Featured | TLR7/8 agonist 1 is a toll-like receptor (TLR7)/TLR8 dual-agonistic imidazoquinoline. |
|
| DC67233 | AYK004-C1 Featured | AYK004-C1 is a TLR agonist. AYK004-C1 can be used to prepare immune adjuvants. |
|
